Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report released on Friday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Stock Performance

Shares of NASDAQ:RKDA opened at $2.93 on Friday. Arcadia Biosciences has a 12 month low of $1.85 and a 12 month high of $4.19. The company has a market capitalization of $3.99 million, a price-to-earnings ratio of -0.57 and a beta of 1.34. The firm’s 50-day moving average is $2.85 and its 200 day moving average is $2.67.

Arcadia Biosciences (NASDAQ:RKDA) last released its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $0.95 million. Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. During the same quarter in the previous year, the business earned ($2.64) EPS. As a group, equities analysts forecast that Arcadia Biosciences will post -1.7 EPS for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.